Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1064137-43-4

3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline is a complex organic compound with the molecular formula C14H8BrCl2N2. It is a derivative of quinoxaline, a fused bicyclic compound consisting of a benzene ring fused to a diazine ring. This particular compound features a bromine atom attached to a methyl group, a chlorine atom at the 5-position, and a 2-chlorophenyl group at the 2-position. It is a halogenated quinoxaline, which may have potential applications in various fields such as pharmaceuticals, agrochemicals, or materials science due to its unique structure and properties. The presence of multiple halogen atoms can influence its reactivity, solubility, and potential for further chemical modifications.

1064137-43-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1064137-43-4 Structure

  • Basic information

    1. Product Name: 3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline
    2. Synonyms: 3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline
    3. CAS NO:1064137-43-4
    4. Molecular Formula:
    5. Molecular Weight: 0
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1064137-43-4.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline(CAS DataBase Reference)
    10. NIST Chemistry Reference: 3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline(1064137-43-4)
    11. EPA Substance Registry System: 3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline(1064137-43-4)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1064137-43-4(Hazardous Substances Data)

1064137-43-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1064137-43-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,4,1,3 and 7 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1064137-43:
(9*1)+(8*0)+(7*6)+(6*4)+(5*1)+(4*3)+(3*7)+(2*4)+(1*3)=124
124 % 10 = 4
So 1064137-43-4 is a valid CAS Registry Number.

1064137-43-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-(bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1064137-43-4 SDS

1064137-43-4Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USES

-

Page/Page column 133, (2008/12/04)

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1064137-43-4